Trial Profile
Protective efficacy of orally delivered bovine milk immunoglobulin (BIgG) specific for the minor CFA/I [colonisation factor antigen I] fimbrial adhesin CfaE against challenge with H10407 enterotoxigenic E. coli [Escherichia coli] (ETEC) strain expressing CFA/I
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bovine anti-Escherichia coli immunoglobulin (Primary)
- Indications Escherichia coli infections
- Focus Adverse reactions
- 20 Mar 2007 New trial record.